Expression of the renal kallikrein gene in mineralocorticoid-treated and genetically hypertensive rats

Peter J. Fuller, Judith A. Clements, Irene Nikolaidis, Masao Hiwatari, John W. Funder

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)


On the basis of both clinical observations and experimental studies it has been proposed that renal kallikrein is a mineralocorticoid regulated protein. In other studies, changes in renal kallikrein activity have been implicated in the genesis of, and/or response to, hypertension. Using a cloned complementary DNA (cDNA) to rat pancreatic kallikrein (pc×P39) for hybridization histochemistry, and both Northern and dot blot analysis, we studied expression of the kallikrein gene in steroid-treated control animals, and in three strains of genetically hypertensive rats. No differences in renal kallikrein messenger RNA (mRNA) levels were found between adrenalectomized rats and those treated for 5-14 days with 9a-fludrocortisone, corticosterone or dexamethasone, or between hypertensive rats and their appropriate controls. Since mRNA levels appear essentially invariant under such circumstances, the change in renal kallikrein activity/immunoreactivity after chronic mineralocorticoid elevation, or in hypertensive rats, presumably reflects modulation at the post-transcriptional level.

Original languageEnglish
Pages (from-to)427-433
Number of pages7
JournalJournal of Hypertension
Issue number4
Publication statusPublished - 1986
Externally publishedYes


  • Gene expression
  • Genetically hypertensive rats
  • Hypertension
  • Mineralocorticoids
  • Renal kallikrein
  • Spontaneously hypertensive rats
  • Wistar-Kyoto rats

Cite this